With one headline, Pfizer had gone from being a well-known hunter — spending heavily to buy rivals — to the hunted.

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

More than 200 brands spoke out in the week that followed Hamas’ terrorist attacks against Israel a year ago. Yet companies ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of ...

“Albert Bourla is very proud of his Greek heritage and of his Jewish heritage, from Thessaloniki,” the Israeli prime minister said. (JTA) — Israel’s government has signed an agreement with ...

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...

WASHINGTON, DC - SEPTEMBER 20: Pfizer CEO Dr. Albert Bourla speaks after U.S. Health ... 2 strain of COVID-19, a member of the Omicron family that resulted in a number of COVID-19 infections ...

Albert Bourla could be seen saying: "We know that the two doses of the vaccine offer very limited protection, if any." Jerome tweeted: "If this video is legit, it has to sound off some alarms ...

They teamed up in 1994 to make biotech investments for members of the Tisch family and launched Baker ... Pfizer Chief Executive Albert Bourla sent Felix a note asking to talk after the J.P ...

Pfizer acquired Seagen, an oncology specialist, for $43 billion. CEO Albert Bourla said of the acquisition: "We are not buying the golden eggs. We are acquiring the goose that is laying the golden ...

Pfizer’s chief executive, Dr. Albert Bourla, said the drug-making company is in a “very advanced stage” and should know by the end of October whether the coronavirus vaccine they are ...

Albert Bourla said Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug candidate. The companies said the vaccine ...